TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32612186
Drug: Placebo (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (600 mg starch in capsule)
Study: 32173607
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) 30 L/min
Study: 32173607
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) 60 L/min
Study: 32912274
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg elacestrant QD (escalated to 400 mg after 14 days)
Study: 32912274
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg elacestrant QD
Study: 32912274
Drug: Elacestrant (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elacestrant (200 mg and 400 mg QD)
Study: 34865095
Drug: Local oxygen‐ozone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local oxygen‐ozone therapy plus medical treatment
Study: 35665526
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy for binge-eating disorder (DBT-BED)
Study: 35665526
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT+)
Study: 33068349
Drug: Routine anti-infection
Normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine anti-infection and symptomatic and supportive treatment (Control Group)
Study: 32740214
Drug: Fractionally ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionally ablative Er:YAG resurfacing, 3 treatments at monthly intervals
Study: 35473348
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage of MKA plus lifestyle modifications
Study: 34187853
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of androgen deprivation therapy (ADT), 6 cycles of radium-223 q28 days, conventionally fractionated prostate radiotherapy (74 Gy) and simultaneous integrated boost to pelvic lymph nodes (60 Gy)
Study: 32922181
Drug: Oxycodone (OXY)
Normalized name: oxycodone hydrochloride Oral Tablet [M-Oxy]
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone (OXY)
Study: 36165862
Drug: Nutrition Bio-shield
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition Bio-shield Superfood (NBS) 4.5 gr daily for 14 days
Study: 34370912
Drug: In-office whitening
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office whitening agent (Opalescence Boost 35%) with light irradiation
Study: 34370912
Drug: In-office whitening
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office whitening agent (Opalescence Boost 35%) without light irradiation
Study: 36203819
Drug: Remimazolam 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam 0.2 mg kg‐1
Study: 34154433
Drug: Peripheral nerve
Normalized name: Peripheral nerve antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral nerve grafting and acidic fibroblast growth factor (aFGF) infusion
Study: 35555099
Drug: High-Iron milk
Normalized name: iron succinyl milk protein complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Iron milk formula (HI) with 480 mg Fe/kg milk solid
Study: 35555099
Drug: Iron-adequate milk
Normalized name: iron succinyl milk protein complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-adequate milk formula (AI) with 60 mg Fe/kg milk solid
Study: 32885995
Drug: Non-steroid anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid anti-inflammatory drugs (NSAIDs)
Study: 33113886
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of spicule technique and nail brace with a polyethylene plastic strip
Study: 36443282
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg daily for 1 week, then 20 mg daily for 1 week, then 10 mg daily for 1 week, plus NSAID for 3 weeks
Study: 33635385
Drug: Low-dose alcohol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alcohol (0.4 g kg−1)
Study: 33635385
Drug: High-dose alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alcohol (0.8 g kg−1)
Study: 32223849
Drug: Modified pedometer-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified pedometer-based Green Prescription
Study: 32223849
Drug: Standard time-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard time-based Green Prescription
Study: 32207984
Drug: Wendan decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wendan decoction (WDD) administered three times daily for more than 1 month, initiated within 14 days of injury.
Study: 34911041
Drug: Dry Needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry Needling (DN) treatment
Study: 34242265
Drug: network-based approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: network-based approach for drug target indication expansion
Study: 32561827
Drug: Herbicide doses
Normalized name: lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbicide doses less than the recommended field application concentration (RFAC)
Study: 32412097
Drug: ECT plus
Normalized name: Protect Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT plus agomelatine 50 mg/day (n = 48)
Study: 35641603
Drug: Collagenase Clostridium
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase Clostridium histolyticum (CCH) injection
Study: 37441289
Drug: Ultrasound (US)
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound (US) guidance for interscalene block with 15 ml 0.5% bupivacaine and 5 ml 2% lignocaine
Study: 37441289
Drug: Nerve stimulator
Normalized name: nerve stimulator device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve stimulator (NS) guidance for interscalene block with 15 ml 0.5% bupivacaine and 5 ml 2% lignocaine
Study: 34495283
Drug: POINT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: POINT group (opt-in narcotic treatment)
Study: 34495283
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine narcotic prescriptions)
Study: 33547218
Drug: Strict phosphate
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict phosphate target range (3.5-4.5 mg/dl)
Study: 33547218
Drug: Standard phosphate
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard phosphate target range (5.0-6.0 mg/dl)
Study: 33040439
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (esomeprazole 20 mg and amoxicillin 750 mg four times daily)
Study: 33040439
Drug: Triple plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple plus bismuth (TPB) therapy (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, and bismuth potassium citrate 220 mg twice daily)
Study: 33040439
Drug: TPB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPB therapy
Study: 33294804
Drug: Landiolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol plus conventional sepsis therapy
Study: 33294804
Drug: Conventional sepsis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional sepsis therapy alone (control group)
Study: 34949538
Drug: 20-mg hyoscine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg hyoscine butylbromide (HBB)
Study: 36183113
Drug: Alum-adjuvanted rabies
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum-adjuvanted rabies vaccine (ARV)
Study: 36183113
Drug: Non-adjuvanted rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted rabies vaccine (NRV)
Study: 33183662
Drug: Carrot seed
Normalized name: carrot seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrot seed (500 mg three times a day for 12 weeks)
Study: 36315128
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg daily after a 1-month phase of 40 mg daily
Study: 32497261
Drug: Induction-concurrent sequence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction-concurrent sequence (induction-PX regimen)
Study: 32497261
Drug: Concurrent-adjuvant sequence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent-adjuvant sequence
Study: 32497261
Drug: 3-arm chemotherapy
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-arm chemotherapy cohort
Study: 35737597
Drug: Palmitoylethanolamide (PEA)
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitoylethanolamide (PEA) 600 mg plus lithium and risperidone
Study: 33989767
Drug: Novel immuno-oncology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel immuno-oncology drugs
Study: 34059016
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioral therapy (CBT)‐based counseling, six in‐person sessions and two telephone sessions once per week after the 14th week of pregnancy.
Study: 32779610
Drug: Self-expanding drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-expanding drug-eluting stent (DES) with a 1-mm larger diameter than the reference vessel diameter
Study: 32779610
Drug: Self-expanding drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-expanding drug-eluting stent (DES) with a 2-mm larger diameter than the reference vessel diameter
Study: 33913339
Drug: Alendronic acid
Normalized name: Alendronic Acid
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronic acid (70 mg once weekly)
Study: 34959148
Drug: 200 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 µg misoprostol
Study: 34111832
Drug: Adequate fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate fruit and vegetable intake (at least twice daily or a combination of at least five times daily)
Study: 34111832
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein food consumption (at least twice weekly)
Study: 34092603
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation and instrument-assisted soft tissue mobilization combined treatment (TICT)
Study: 36172716
Drug: Home hand
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [Home Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home hand therapy
Study: 33929389
Drug: Metformin (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2, 5, 10, and 20 mmol/L)
Study: 32389532
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (24 weeks of hour-long, twice-weekly classes including strength training, aerobic exercise, nutrition education, and civic engagement activities)
Study: 35405991
Drug: Wine (27
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wine (27 g of alcohol/day for 8 weeks)
Study: 35405991
Drug: Ethanol (27
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (27 g of alcohol/day for 8 weeks)
Study: 33184627
Drug: Energy deficit
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy deficit (DEF) at 45% of total daily energy expenditure
Study: 33184627
Drug: Energy matched
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy matched (BAL) to individual estimated total daily energy expenditure (±10%)
Study: 34762376
Drug: Abdominal acupoint
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal acupoint thread embedding therapy combined with donepezil hydrochloride tablets (5 mg per day)
Study: 34762376
Drug: Donepezil hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil hydrochloride tablets (5 mg per day)
Study: 32389658
Drug: Dabigatran dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran dual therapy (110 mg or 150 mg twice daily)
Study: 32389658
Drug: Warfarin triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin triple therapy (warfarin, aspirin, and a P2Y12 platelet inhibitor)
Study: 35611667
Drug: Synbiotic containing
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic containing Lactobacillus paracasei DKGF1 and Opuntia humifusa, administered once a day for 4 weeks
Study: 35611667
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered once a day for 4 weeks
Study: 34352125
Drug: Triangular neck
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triangular neck (TN) implants
Study: 34352125
Drug: Round neck
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Round neck (RN) implants
Study: 34352125
Drug: Both TN
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both TN and RN implants
Study: 35168964
Drug: Healthy food
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy food prescription incentive (n=297) with a weekly incentive of CDN$10.50/household member for 6 months
Study: 35168964
Drug: Healthy food
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy food prescription comparison group (n=297)
Study: 36567637
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L polyethylene glycol plus ascorbic acid with 24 mg senna (1L-PEG/AS)
Study: 36567637
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L polyethylene glycol plus ascorbic acid (2L-PEG/A)
Study: 32731903
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (no specific dosage or duration mentioned)
Study: 35895770
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg CBD in oil (oral)
Study: 35895770
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg CBD in DMSO (IV)
Study: 32722729
Drug: NSI-189 80-mg
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSI-189 80-mg dose
Study: 32722729
Drug: NSI-189 40-mg
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSI-189 40-mg dose
Study: 32722729
Drug: NSI-189 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSI-189 (both doses)
Study: 36294918
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of mometasone furoate twice daily along with olfactory training
Study: 33852250
Drug: Carboxytherapy gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxytherapy gel mask
Study: 33852250
Drug: Petroleum-based lanolin-containing
Normalized name: lanolin / petrolatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petroleum-based lanolin-containing ointment
Study: 35236066
Drug: Total Cryotherapy
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Cryotherapy (TCT) + Transcranial Magnet Therapy
Study: 36128988
Drug: Modular cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modular cognitive behavioral therapy (M-CBT)
Study: 32868016
Drug: IN.PACT drug-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN.PACT drug-coated balloon (DCB)
Study: 34889205
Drug: Serum steroid
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum steroid levels
Study: 32816246
Drug: Brigatinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib (oral tyrosine kinase inhibitor)
Study: 34724257
Drug: Rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1 mg/day over 12 months
Study: 32651892
Drug: Carriers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carriers of the rs2175898 G allele
Study: 33675347
Drug: Antenatal iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal iron supplementation (60 mg elemental iron as ferrous fumarate daily from 13-23 weeks of gestation until 1 month postpartum)
Study: 35792881
Drug: 10-tablet default
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-tablet default
Study: 35792881
Drug: 5-tablet default
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-tablet default
Study: 35667420
Drug: Surgery with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery with intrauterine instillation of hyaluronic acid gel
Study: 33557254
Drug: Dog-assisted therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dog-assisted therapy based on the Comprehensive Cognitive Activation Program in Dementia for 8 months, with weekly sessions of 45 min
Study: 32539076
Drug: rAAVrh74.MHCK7.micro-dystrophin, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAVrh74.MHCK7.micro-dystrophin, single dose of 2.0 × 10^14 vg/kg infused through a peripheral limb vein, daily prednisolone 1 mg/kg starting 1 day before gene delivery (30-day taper after infusion)
Study: 36382358
Drug: EDP-514 200
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-514 200 mg
Study: 36382358
Drug: EDP-514 400
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-514 400 mg
Study: 36382358
Drug: EDP-514 800
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-514 800 mg
Study: 34338114
Drug: Resveratrol-based multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol-based multivitamin supplement
Study: 34843669
Drug: Optimised regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised regimen (25 mg/kg loading dose, followed by 15 mg/kg every 12 h or 8 h for 5 ± 1 days)
Study: 34843669
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (no loading dose; 15 mg/kg every 24 h, 12 h, or 8 h for 10 ± 2 days)
Study: 32349692
Drug: Online guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online guided self-help Cognitive Behavioral Therapy-Enhanced intervention
Study: 35320161
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) administered at the same rate as lidocaine
Study: 34306189
Drug: Intravenous and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and/or nebulized neutral electrolyzed saline combined with usual medical care
Study: 35294397
Drug: Tesomet (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesomet (0.5 mg tesofensine/50 mg)
Study: 36260302
Drug: cCDT (alteplase,
Approvals — FDA: no, EMA: no, PMDA: no
Description: cCDT (alteplase, 0.5 mg/catheter/h for 24 hours) plus heparin
Study: 36260302
Drug: Anticoagulation monotherapy
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation monotherapy
Study: 32861428
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and parenteral pharmacological agents for spasticity management
Study: 35432560
Drug: Jie Yu
Normalized name: Yu Jin
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jie Yu Wan (JYW) high dose (24 g/day)
Study: 35432560
Drug: Buspirone high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone high dose (30 mg/day)
Study: 35432560
Drug: Jie Yu
Normalized name: Yu Jin
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jie Yu Wan (JYW) low dose (12 g/day)
Study: 35432560
Drug: Buspirone low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone low dose (15 mg/day)
Study: 33034707
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of olive leaf extract (OLE) for 8 weeks
Study: 32217429
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (25 mg, 50 mg, 75 mg)
Study: 32735021
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma injections
Study: 33096517
Drug: Control (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sham subcutaneous infiltration)
Study: 39549678
Drug: Crizotinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib (250 mg twice daily)
Study: 36057376
Drug: Choice architecture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice architecture intervention to nudge clinicians toward non-opioid treatments for opioid-naïve patients.
Study: 36057376
Drug: Integration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integration of the prescription drug monitoring program (PDMP) within the EHR.
Study: 33666270
Drug: Probiotic supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplements (3.2 × 10^9 CFU per day for 12 weeks)
Study: 33666270
Drug: Placebo (empty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (empty capsules filled with starch)
Study: 36112778
Drug: Gimsilumab (anti-Granulocyte–Macrophage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gimsilumab (anti-Granulocyte–Macrophage Colony–Stimulating Factor Monoclonal Antibody)
Study: 33218878
Drug: Oral carbohydrate
Normalized name: omega-3 carboxylic acids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbohydrate (OCH)-rich drink
Study: 33218878
Drug: Intravenous dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dextrose 10% infusion